Literature DB >> 27339942

Immune signaling-based Cascade Propagation approach re-stratifies HNSCC patients.

Keqin Liu1, Jacqueline Chyr2, Weiling Zhao1, Xiaobo Zhou3.   

Abstract

The availability of high-throughput genomic assays and rich electronic medical records allows us to identify cancer subtypes with greater accuracy and resolution. The integration of multiplatform, heterogenous, and high dimensional data remains an enormous challenge in using big data in bioinformatics research. Previous methods have been developed for patient stratification, however, these approaches did not incorporate prior knowledge and offer limited biology insight. New computational methods are needed to better utilize multiple types of information to identify clinically meaningful subtypes. Recent studies have shown that many immune functional genes are associated with cancer progression, recurrence and prognosis in head and neck squamous cell carcinoma (HNSCC). Therefore, we developed a novel immune signaling based Cascade Propagation (CasP) subtyping approach to stratify HNSCC patients. Unlike previous stratification methods that use only patient genomic data, our approach makes use of prior biological information such as immune signaling and protein-protein interactions, as well as patient survival information. CasP is a multi-step stratification procedure, composed of a dynamic network tree cutting step followed by a mutational stratification step. Using this approach, HNSCC patients were first stratified into clinically relative subgroups with different survival outcomes and distinct immunogenic features. We found that the good outcome of a subgroup of HNSCC patients was due to an enhanced immune response. The gene sets were characterized by a significant activation of T cell receptor signaling pathways, in addition to other important cancer related pathways such as PI3K and JAK/STAT signaling pathways. Further stratification of patients based on somatic mutation profiles detected three survival-distinct subnetworks. Our newly developed CasP subtyping approach allowed us to integrate multiple data types and identify clinically relevant subtypes of HNSCC patients. Copyright Â
© 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Cascade Propagation subtyping; Immune signaling; Patient stratification

Mesh:

Substances:

Year:  2016        PMID: 27339942      PMCID: PMC6029246          DOI: 10.1016/j.ymeth.2016.06.018

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  51 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Learning the parts of objects by non-negative matrix factorization.

Authors:  D D Lee; H S Seung
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

Review 3.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

Review 4.  TLR signalling and the function of dendritic cells.

Authors:  Hiroaki Hemmi; Shizuo Akira
Journal:  Chem Immunol Allergy       Date:  2005

Review 5.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Authors:  Stephen Y Lai; Faye M Johnson
Journal:  Drug Resist Updat       Date:  2010-05-14       Impact factor: 18.500

6.  LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.

Authors:  W Zhang; J Sloan-Lancaster; J Kitchen; R P Trible; L E Samelson
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

Review 7.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

8.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.

Authors:  Vivian W Y Lui; Matthew L Hedberg; Hua Li; Bhavana S Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R Gilbert; Maria Freilino; Sam Sauerwein; Noah D Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A Garraway; Peter S Hammerman; Gordon B Mills; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2013-04-25       Impact factor: 39.397

9.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

10.  Associating genes and protein complexes with disease via network propagation.

Authors:  Oron Vanunu; Oded Magger; Eytan Ruppin; Tomer Shlomi; Roded Sharan
Journal:  PLoS Comput Biol       Date:  2010-01-15       Impact factor: 4.475

View more
  2 in total

Review 1.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

2.  Development of an Immunogenomic Landscape-Based Prognostic Index of Head and Neck Squamous Cell Carcinoma.

Authors:  Jinhua Long; Shichao Zhang; Xianlin Zeng; Yan Ouyang; Yun Wang; Zuquan Hu; Yuannong Ye; Weili Wu; Feng Jin; Shi Zhou; Zhu Zeng
Journal:  Front Mol Biosci       Date:  2020-11-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.